Drug intelligence / Profile preview

89Zr-βG-Fab

Development stage: Preclinical
Lead developer: National Institutes of Health
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

89Zr-βG-Fab is a zirconium-89 labeled anti-β-glucan antibody fragment (Fab) developed by the National Institutes of Health (NIH) as a pan-fungal positron emission tomography (PET) imaging tracer. The tracer consists of a Fab fragment derived from a high-affinity rabbit anti-β-glucan IgG antibody (clone B3149M) conjugated to the chelator desferrioxamine (DFO) and radiolabeled with zirconium-89 (89Zr). It specifically targets β-glucans, which are conserved polysaccharide components of the fungal cell wall absent in mammalian cells and most bacteria. 89Zr-βG-Fab is designed for the non-invasive detection and localization of invasive fungal infections, including those caused by Aspergillus, Candida, and Mucorales species, offering rapid clearance and high specificity compared to full-length antibodies.

Other names: 89Zr-DFO-HA-βG-Fab89Zr-HA-βG-Fab89Zr-labeled anti-beta-glucan Fab89Zr-labeled anti-beta-glucan antibody Fab89Zr-labeled anti-β-glucan Fab89Zr-labeled anti-β-glucan antibody Fab[89Zr]Zr-DFO-HA-βG-Fab

Beyond the preview

Go deeper on 89Zr-βG-Fab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 89Zr-βG-Fab.